LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Summary Public Assessment Report

Bupropion SUN
(bupropion hydrochloride)

SE/H/2459/01-02/DC

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

Summary Public Assessment Report

Bupropion SUN
bupropion hydrochloride

Modified-release tablet, 300 mg, 150 mg

This is a summary of the public assessment report (PAR) for Bupropion SUN. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Bupropion SUN and what is it used for?

The product is a 'generic medicine'. This means that it is similar to a 'reference medicine' already authorised in the European Union (EU) called Voxra (this product is also approved under the product names Wellbutrin XR or Elontril within the EU).

The product is used in the treatment of depression.

How does Bupropion SUN work?

The product is thought to interact with chemicals in the brain called noradrenaline and dopamine.

How is Bupropion SUN used?

The pharmaceutical form is modified-release tablets for oral use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Bupropion SUN have been shown in studies?

Because the product is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Voxra. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the possible side effects from Bupropion SUN?

Because the product is a generic medicine, its benefits and possible side effects are taken as being the same as the reference medicine.
For the full list of side effects, see section 4 of the package leaflet.
For the full list of restrictions, see the package leaflet.

Why is Bupropion SUN approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be bioequivalent to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Voxra, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Bupropion SUN?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.
Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Bupropion SUN

The full PAR for Bupropion SUN can be found on the following website: http://mri.medagencies.org/Human/. For more information about treatment with Bupropion SUN, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2024-10.